Nionyx Bio builds AAV-based gene therapies to address some of the most potent kidney genetic diseases.
Nionyx Bio has raised $4.0M in total funding. The most recent round was Seed. The last funding was announced in September 2025.
Nionyx Bio's investors include 2048 Ventures, AIN Ventures, New York Ventures, Pathway Bioventures, White Mug Healthcare.
Nionyx Bio is headquartered in New York, United States.
Nionyx Bio builds AAV-based gene therapies to address some of the most potent kidney genetic diseases.
Nionyx Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nionyx Bio — Funding & Investors." VCBacked, September 29, 2025, https://www.vcbacked.co/company/nionyx-bio. Accessed November 12, 2026.
VCBacked. (2025). Nionyx Bio — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/nionyx-bio
{{cite web |title=Nionyx Bio — Funding & Investors |url=https://www.vcbacked.co/company/nionyx-bio |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Nionyx Bio? Request a listing update